Product Description
Mechanisms of Action: M1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Chile | Ecuador | Egypt | Indonesia | Japan | Malaysia | Mexico | Philippines | Russia | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: ONO Pharm
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Overactive Bladder|Urinary Incontinence, Urge
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20242398 |
CTR20242398 | P1 |
Completed |
Urinary Incontinence, Urge|Overactive Bladder |
2024-08-27 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |